MONTREAL, QUEBEC -- (MARKET WIRE) -- 06/09/2006 -- Mistral Pharma Inc. (TSX-VENTURE: MIP) (the "Corporation", "Mistral") announces today its financial results and review of operating highlights for the year ended March 31, 2006. "The highlight of Mistral's first year as a publicly traded company was MIST-B01's successful pilot clinical study which positions Mistral as a proven branded product developer" said Mr. Bertrand Bolduc, the Corporation's President & CEO. "The successful private placement of $5 million closed in May 2006 will allow us to focus on the development of our product line" he added.
